US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Akili Interactive
Shionogi Begins Phase 3 Study in Japan of Akili’s Digital Treatment in Children with ADHD
August 01, 2022
From
Akili Interactive
Via
Business Wire
Akili Announces Public Company Board of Director Nominees
July 11, 2022
From
Akili Interactive
Via
Business Wire
Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer
June 06, 2022
From
Akili Interactive
Via
Business Wire
Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox
May 26, 2022
From
Akili Interactive
Via
Business Wire
Tickers
DNAA
RBLX
The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactive’s Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults with Major Depressive Disorder When Combined with Antidepressant Medication
April 12, 2022
From
Akili Interactive
Via
Business Wire
Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit
April 04, 2022
From
Akili Interactive
Via
Business Wire
Tickers
DNAA
Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer
March 17, 2022
From
Akili Interactive
Via
Business Wire
Tickers
DNAA
Akili to Speak on Integrating Digital Therapeutics Into Mainstream Healthcare at DTx West 2022
February 18, 2022
From
Akili Interactive
Via
Business Wire
Tickers
DNAA
Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I
February 14, 2022
From
Akili Interactive
Via
Business Wire
Tickers
DNAA
Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
January 26, 2022
From
Akili Interactive
Via
Business Wire
Tickers
DNAA
Akili Founders Recognized by Newsweek on Inaugural List of America’s 50 Greatest Disruptors
December 17, 2021
From
Akili Interactive
Via
Business Wire
Topline Results from Shionogi Phase 2 Study in Japan Show Akili’s Digital Treatment Was Well-received and Improved Inattention Symptoms in Children with ADHD
September 29, 2021
From
Akili Interactive
Via
Business Wire
Akili Announces EndeavorRx® Is Now Available on Android™ Devices, Expanding Access for Children with ADHD
September 16, 2021
From
Akili Interactive
Via
Business Wire
Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments
August 17, 2021
From
Akili Interactive
Via
Business Wire
Tickers
ASX:TD1
Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children with ADHD
July 22, 2021
From
Akili Interactive
Via
Business Wire
Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
May 26, 2021
From
Akili Interactive
Via
Business Wire
Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Treatment for Patients with COVID Brain Fog
April 07, 2021
From
Akili Interactive
Via
Business Wire
